Skip to main content
Premium Trial:

Request an Annual Quote

NextBio, Sanofi Collaborate on Translating Molecular Data

NEW YORK (GenomeWeb News) – NextBio today announced it has forged a multiyear deal with Sanofi for use of the NextBio Clinical platform in the drug manufacturer's R&D work.

Sanofi will use the platform for aggregating, standardizing, and analyzing patient clinical data, next generation sequencing, and other molecular data across public data sources, Sanofi's clinical trials, and Sanofi's hospital partners, NextBio said. Sanofi is using the NextBio Clinical platform as part of its Translational Medicine for Patients program.

NextBio said that the system will allow Sanofi to leverage a vast and growing pool of patient data for translational and clinical research.

"The new translational medicine partnership with NextBio, with its big data genomics capabilities, will enable Sanofi to implement patient-centered approaches across all stages of translational and clinical research in several major therapeutic areas, including oncology and diabetes," NextBio President and CEO Saeid Akhtari said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.